Session(s)
- The Minimal Important Difference of the Tricuspid Annular Plane Systolic Excursion in Scle...
Sunday, May 20 11:15 AM - 1:00 PM - Baseline and Demographic Data on the First 250 Patients from SPHERE (UptraviĀ® [SelexiPag]:...
Tuesday, May 22 11:15 AM - 1:00 PM - Change in Objective Parameters After Long-Term Selexipag Therapy for Pulmonary Arterial Hy...
Tuesday, May 22 11:15 AM - 1:00 PM - Hemodynamic Effects of Fluoxetine in Pulmonary Arterial Hypertension (PAH)- An Open Label ...
Tuesday, May 22 11:15 AM - 1:00 PM - Mortality in Pulmonary Arterial Hypertension Patients Treated with Continuous Prostanoids ...
Tuesday, May 22 11:15 AM - 1:00 PM - Parenteral Prostanoids in the Treatment of Stimulant-Use Associated Pulmonary Arterial Hyp...
Tuesday, May 22 11:15 AM - 1:00 PM - Patient Characteristics and Treatment Patterns in the Largest Real-World Cohort of Pulmona...
Tuesday, May 22 11:15 AM - 1:00 PM - Transitions from Inhaled, Intravenous, Subcutaneous, or Oral Prostacyclins to Selexipag: I...
Tuesday, May 22 11:15 AM - 1:00 PM - Association of NT-proBNP and Long-Term Outcome in Pulmonary Arterial Hypertension (PAH): I...
Wednesday, May 23 1:30 PM - 3:30 PM - Early Initiation of Intravenous Prostanoid Therapy Is Associated with Improved Outcomes in...
Wednesday, May 23 1:30 PM - 3:30 PM - Real-World Dosing and Titration of Selexipag in Patients with Pulmonary Arterial Hypertens...
Wednesday, May 23 1:30 PM - 3:30 PM